Medicare reimbursement, working with Congress on legislation relating to the early detection and treatment of deadly diseases.
2025 · 4th Quarter (Oct 1 - Dec 31)
TELIX PHARMACEUTICALS US
Filed by LIBERTY PARTNERS GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 21, 2026
- Income
- $52,000.00
- Expenses
- Not reported
- Registrant
- LIBERTY PARTNERS GROUP, LLC
- Client
- TELIX PHARMACEUTICALS US
- Filing UUID
- 9cbe3828-476b-44c2-8af6-c0e95bea7159
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Medicare reimbursement, working with Congress on legislation relating to the early detection and treatment of deadly diseases.
Medicare reimbursement, working with Congress on legislation relating to the early detection and treatment of deadly diseases.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.